11 lectures · 106 items
11 min
17 min
16 min
45 min
7 min
20 min
10 min
4 min
2 min
4 min
10 min
EU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular Health
Sex Differences and Trends in Cardiovascular Risk Management: Insights from a Long-Term Primary Care Study
Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) in Primary care: A Systematic Review of Guidelines
Study on Cardiovascular Risk Factors and Primary Care Utilization in Spain
The Vital Role of Primary Care in Advancing Cardiovascular Health
Global Insights from the INTERASPIRE Study: Mapping Lipoprotein(a) Prevalence in Coronary Heart Disease Across Six WHO Regions
Enhancing CVD Risk Assessment: Integrating Genetic Risk for Improved Prediction
Web app effective in determining access to statins without a prescription
Enhanced remote medication program boosts GDMT prescriptions for high CV or kidney risk in T2D patients
Gamification and financial incentives to increase physical activity among patients at elevated CV risk
STRATIFY-HF A European collaboration to develop an AI based support system for risk stratification and early detection of heart failure
Global Shift: From Underweight to Obesity Dominance in Three Decades Across Generations
EPCCS Practical Guidance on Heart Failure Diagnosis and Management in Primary Care
EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary carethe glucagon/GLP-1 dual agonist survodutide does not raise cardiovascular risk in obesity (5-point MACE HR 0.89), delivers 13.7 percent weight loss and 6.7 mmHg lower blood pressure, but one in five stops for gastrointestinal effects
Presented in LBS.05 at AHA 2026 (Monday 9 November) by principal investigator Biykem Bozkurt and published simultaneously in The Lancet; the figures below come from the Boehringer Ingelheim release…
the once-daily GLP-1 pill orforglipron lowers the apnoea-hypopnoea index in moderate to severe sleep apnoea with obesity by 12 to 13 events per hour more than placebo, with 10 percent weight loss and 7 mmHg lower blood pressure
Presented in LBS.05 at AHA 2026 (Monday 9 November) by Vaishnavi Kundel (Mount Sinai) and published simultaneously in JAMA (first author Atul Malhotra). ATTAIN-OSA comprises two 52-week, phase 3…
the ANGPTL4 antibody MAR001 lowers triglycerides up to 45.5 percent more than placebo without worsening glucose, and a single CRISPR infusion against ANGPTL3 removes 63 percent of triglycerides in ten patients with severe hypertriglyceridaemia
Two early-phase lipid trials from LBS.05 at AHA 2026 (Monday 9 November). TYDAL-TIMI 78 Part A, presented by Michelle O'Donoghue (TIMI Study Group) and published simultaneously in NEJM: 235 adults…
patients who received vutrisiran from the start of HELIOS-B have 37 percent fewer deaths or cardiovascular events through month 48 than those who began after the placebo phase, and eplontersen measurably shrinks myocardial amyloid on MRI in CARDIO-TTRansform
Two Circulation papers behind FS.11 at AHA 2026 (Monday 9 November); figures from the published abstracts. HELIOS-B open-label extension (Garcia-Pavia et al., online 3 November; Peter van der Meer of…
in moderate aortic stenosis with at-risk features, upfront TAVR gives fewer deaths or heart-failure events at two years than clinical surveillance (16.7 versus 23.9 percent), but the gain lies entirely in heart failure and not in mortality
Presented again in FS.13 at AHA 2026 (Monday 9 November) after its TCT 2026 debut and NEJM publication of 2 November. PROGRESS randomised 744 patients (mean age 78, 39.1 percent women, 45.6 percent…
dapagliflozin slows the loss of kidney function in heart transplant recipients, with Rotterdam, Groningen and Utrecht as three of the six centres
Presented in FS.07 at AHA 2026 (Sunday 8 November) and published simultaneously in Circulation. DAPARHT (Dapagliflozin for Renal Protection in Heart Transplant Recipients) is an…
a single ferric derisomaltose infusion improves peak VO2, walking distance and NYHA class at twelve weeks in HFpEF with iron deficiency, but not patient-reported health status
Presented in FS.07 at AHA 2026 (Sunday 8 November, Gregory D. Lewis, Mass General Brigham, Boston) and published simultaneously in Circulation. IRONMET-HFpEF is a single-centre, double-blind…
in atrioventricular block, left bundle branch pacing cuts death, heart failure hospitalisation or pacing-induced cardiomyopathy by 59 percent compared with conventional right ventricular pacing; the trial was stopped early
Presented in LBS.04 at AHA 2026 (Sunday 8 November) and published simultaneously in NEJM. OptimPacing is an investigator-initiated, open-label randomised trial at 17 centres in mainland China, Hong…
ablating low-voltage areas on top of pulmonary vein isolation does not significantly reduce recurrence of persistent atrial fibrillation overall, but does in the half of patients who have such areas
Presented in LBS.04 at AHA 2026 (Sunday 8 November) and published simultaneously in JAMA. COAST-AF (Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation) is a…
five years of CPR education, dispatcher training and extra AEDs in 31 North Carolina counties did not yield more survivors with good brain function than usual practice in 29 others
Presented in LBS.04 at AHA 2026 (Sunday 8 November) and published simultaneously in NEJM. RACE-CARS is a cluster-randomised trial of 60 North Carolina counties (about 8.5 million residents), 31…
upfront PCI on top of optimal medical therapy does not lower death or myocardial infarction in stable coronary disease, hazard ratio 1.01 in 959 veterans
Presented in FS.01 at AHA 2026 (Saturday 7 November) and published as a research letter in JAMA. Post hoc extended observational follow-up of 959 of the 2,287 COURAGE participants (42 percent), the…
stopping statins in multimorbid adults aged 70 and over without cardiovascular disease meets the noninferiority margin but gives 38 percent more deaths, infarctions and strokes
Presented in LBS.03 at AHA 2026 (Saturday 7 November) and published simultaneously in NEJM. STREAM randomised 1,880 adults aged 70 or over (mean 77.5, 46.9 percent women, 32.1 percent diabetes, 53.5…